LUNG CANCER HARB ORING HER2 MUTATION :EPIDE MIOLOGI CAL CHARACTE RISTICS AND5 `1 [1 k) y, g# Y8 g
THERAPE UTIC PERSPECTIVES I* F4 }4 N, O
J. Mazieres, S. Peters
p7 n8 I4 [9 K4 wIntroduction: HER2 oncogene is a memb er of the EGFR family, encoding atransmembrane receptor that drives and regulates cell proliferation. HER2 mutations are identified in about 2% of non small cell lung cancer (NSCLC) , mainly located in exon 20, and appear to be critical for lung cancer carcinogenesis . Very scarce data are available to define a clinical profile of the patients harboring HER2 mutated NSCLC. We aimed to study clinic opatholog ical characteristics an d therapeutic
0 t: ] E8 d/ A/ _) Ooutcomes of patients harboring HER2 mutation in a large European series. Result s:We retrospec tively ide ntified 46 NSCLC patients diagn osed with HER2 exon 20 mut ation. HER2 mutation was mainly exclusive as only one concomitan t KRas mutation was des cribed. Our population was characterized by a median age of 60 yr (31 to 86 yr), a high proportion of women (30 vs. 16 men, 65% ), and of never smokers (24, 52%). All tumors were adenoc arcinomas (two with lepidic features). Half of the patients had stage IV dise ase at the time of diagnosis. HER2 targeted- i: k+ W7 D# k$ s
treatment was delivered after convention al chemothe rapy. A total of 20 anti-Her2
W. n. K; w; V! _0 J) wtreatments were eval uable. We observed 4 progressive dise ases, 7 disease stabilizations
3 ]9 x6 S6 V* |6 wand 9 partial resp onses according to RECIST 1.1 (overall response rate ORR = 45% ;
) D" h, C2 _ }6 Zdisease control rate DCR = 80%). Specifica lly, we obse rved a DCR of 92% for
- x+ b* ~8 k! Y! N# k0 r0 jtrastuzum ab-based therapie s (n = 14), 100 % for afatinib (n = 3) but no response to! K9 H% m$ E# p, a
lapatinib (n = 2) and to a multiTKI (n = 1). Median survival was of 68.2 months and: W4 [1 G0 o) m! m; G& D
22.9 months for respectively early stage and stag e IV patients.0 \7 i4 V' V7 u e
Conclusion: This study, the largest to date dedic ated to HER2 mutated NSCLC,2 |3 n- W: X9 y# C+ k
reinforces the importance of an HER2 screening strategy in lung adenoc arcinomas .
3 c ~6 u9 p# qHER2-target ed drugs shou ld be tested further, ide ally withi n large collaborative: @6 P! e' v0 |/ h9 ^
clinicaltrials.* ?5 j) D8 l$ y
|
显身卡
